List of Unity Biotechnology patents

List of Unity Biotechnology patents

List of Iron Mountain (company) patents

List of Qlt Inc. patents

List of Global OLED Technology LLC patents

List of companies in Rebel Venture Fund's investment portfolio

List of Avidity Biosciences patents

Patents where

Current Assignee

Name

is

Unity Biotechnology

	Name	Description	Patent Applicant	Current Assignee	Inventor	Patent Jurisdiction	Patent Number	Date of Patent
	‌ US Patent 10588916 Technology to inhibit vascular changes that lead to vision loss in the eye	Patent 10588916 was granted and assigned to Unity Biotechnology on March, 2020 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10588916	March 17, 2020
	‌ US Patent 10519197 Peptide-based proteasome inhibitors for treating conditions mediated by senescent cells and for treating cancer	Patent 10519197 was granted and assigned to Unity Biotechnology on December, 2019 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10519197	December 31, 2019
	‌ US Patent 10329279 Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use	Patent 10329279 was granted and assigned to Unity Biotechnology on June, 2019 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10329279	June 25, 2019
	‌ US Patent 9988368 Chiral synthesis method for producing cis-imidazoline compounds for pharmaceutical use	Patent 9988368 was granted and assigned to Unity Biotechnology on June, 2018 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	9988368	June 5, 2018
	‌ US Patent 10738042 Phosphonamidates that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer		Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10738042	August 11, 2020
	‌ US Patent 10717722 Acyl sulfonamides that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer	Patent 10717722 was granted and assigned to Unity Biotechnology on July, 2020 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10717722	July 21, 2020
	‌ US Patent 10745429 Phospholidines that are Bcl family antagonists for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer	Patent 10745429 was granted and assigned to Unity Biotechnology on August, 2020 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10745429	August 18, 2020
	‌ US Patent 11111259 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders	Patent 11111259 was granted and assigned to Unity Biotechnology on September, 2021 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	11111259	September 7, 2021
	‌ US Patent 10426788 Chemical entities that kill senescent cells for use in treating age-related disease	Patent 10426788 was granted and assigned to Unity Biotechnology on October, 2019 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	10426788	October 1, 2019
	‌ US Patent 9969776 Drug conjugates for delivering compounds to senescent cells	Patent 9969776 was granted and assigned to Unity Biotechnology on May, 2018 by the United States Patent and Trademark Office.		Unity Biotechnology		United States Patent and Trademark Office	9969776	May 15, 2018
	‌ US Patent 11951115 Methods of treating retinal vasculopathies	Patent 11951115 was granted and assigned to Unity Biotechnology on April, 2024 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	11951115	April 9, 2024
	‌ US Patent 11865123 Methods of inhibiting pathological angiogenesis	Patent 11865123 was granted and assigned to Unity Biotechnology on January, 2024 by the United States Patent and Trademark Office.	Unity Biotechnology	Unity Biotechnology		United States Patent and Trademark Office	11865123	January 9, 2024

12 results

0 selected

12 results

0 selected